| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advances in the clinical management of GVHD
|
Ferrara, James L.M.
|
|
2008
|
21 |
4 |
p. 677-682
6 p.
|
artikel
|
| 2 |
Aims & scope/editorial board
|
|
|
2008
|
21 |
4 |
p. iii-
1 p.
|
artikel
|
| 3 |
Are new agents really making a difference in MDS?
|
Stone, Richard M.
|
|
2008
|
21 |
4 |
p. 639-646
8 p.
|
artikel
|
| 4 |
Can we finally target the leukemic stem cells?
|
Jordan, Craig T.
|
|
2008
|
21 |
4 |
p. 615-620
6 p.
|
artikel
|
| 5 |
Clinical progress in acute myeloid leukemia
|
Rowe, Jacob M.
|
|
2008
|
21 |
4 |
p. 597-599
3 p.
|
artikel
|
| 6 |
Diagnosis and therapy of fungal infection in patients with leukemia—new drugs and immunotherapy
|
Anaissie, Elias J.
|
|
2008
|
21 |
4 |
p. 683-690
8 p.
|
artikel
|
| 7 |
Index
|
|
|
2008
|
21 |
4 |
p. I-II
nvt p.
|
artikel
|
| 8 |
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
|
Douer, Dan
|
|
2008
|
21 |
4 |
p. 647-658
12 p.
|
artikel
|
| 9 |
Is the focus moving toward a combination of targeted drugs?
|
Grant, Steven
|
|
2008
|
21 |
4 |
p. 629-637
9 p.
|
artikel
|
| 10 |
Molecular characterization of AML: A significant advance or just another prognostic factor?
|
Schiffer, Charles A.
|
|
2008
|
21 |
4 |
p. 621-628
8 p.
|
artikel
|
| 11 |
Tumor suppressor gene inactivation in myeloid malignancies
|
Wong, Jasmine C.
|
|
2008
|
21 |
4 |
p. 601-614
14 p.
|
artikel
|
| 12 |
What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?
|
Anasetti, Claudio
|
|
2008
|
21 |
4 |
p. 691-697
7 p.
|
artikel
|
| 13 |
What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?
|
Appelbaum, Frederick R.
|
|
2008
|
21 |
4 |
p. 667-675
9 p.
|
artikel
|
| 14 |
What is the role of arsenic in newly diagnosed APL?
|
Tallman, Martin S.
|
|
2008
|
21 |
4 |
p. 659-666
8 p.
|
artikel
|
Tijdschrift beschrijving